> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AEMS May Mean Increased Stakeholder Scrutiny: Column
- URL: https://www.fdaweb.com/aems-may-mean-increased-stakeholder-scrutiny-column/
- Published: 2026-05-13T12:00:00.000Z
- Updated: 2026-09-14T13:39:12.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161134

Three Morgan Lewis attorneys say the FDA 3/11 launch of its new Adverse Event Monitoring System ([AEMS](https://www.fda.gov/news-events/press-announcements/fda-launches-new-adverse-event-look-tool?ref=fdaweb.com)) “marks an important evolution in safety data transparency and accessibility, offering single-platform advanced analytics and real-time information for drugs, biologics, cosmetics, and vaccines, with medical device data to be added in the near future.” The attorneys [caution](https://www.jdsupra.com/legalnews/adverse-events-centralized-what-the-1361704/?ref=fdaweb.com) in an online column that while current reporting obligations remain unchanged, the ease of data access and visualization may prompt increased scrutiny from various stakeholders. “Companies should stay engaged with the rollout, understand the system’s capabilities, and anticipate new forms of external analysis and inquiry,” they say.

These are the key takeaways the attorneys cite:

- FDA launched a centralized, real-time adverse event monitoring system that will eventually unify all FDA adverse event databases with AI-enabled, near real-time data and enhanced analytics;
- at launch, AEMS includes data for drugs, biologics, cosmetics, and vaccines with medical devices and remaining product areas scheduled for integration by the end of May;
- if the AEMS functions for drugs and biologics signal the functionality for devices, AEMS will provide greater data access and usability: expanded historical data, visualization tools, and cross-product comparisons make analysis easier for external users; and
- easier data access may drive more stakeholder scrutiny and potential misinterpretations, requiring proactive monitoring by companies.

The column cites these practical implications for companies and industry stakeholders:

- increased public and legal scrutiny; and
- real-time data monitoring.

“While the system warns users about the limitations of the data (e.g., it may be inaccurate and include unverified claims), there is an increased risk that external parties may misinterpret or take data out of context when conducting their own reviews,” the attorneys write. “Companies should consider proactively familiarizing themselves with AEMS’s features and monitoring how their products are represented in the new database. Internal stakeholder education regarding the data’s limitations and context may also help mitigate reputational or legal risks associated with potential misinterpretation of adverse event trends. Organizations may want to prepare for an uptick in inquiries from external parties who can now more easily access and analyze comprehensive adverse event data.”